CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.
Styliani Vlachou, George G. Nomikos, George Panagis
Psychopharmacology May 2005 DOI: 10.1007/s00213-004-2050-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Male Sprague-Dawley rats |
| Interventions | WIN 55 212-2 CP 55 940 HU-210 SR141716A AM 251 |
| Dose | WIN 55,212-2 0.1, 0.3, 1, 3 mg/kg; CP 55,940 10, 30, 56, 100 microg/kg; HU-210 10, 30, 100 microg/kg; SR141716A and AM 251 doses not specified |
| Measures | rate-frequency curve shift paradigm of intracranial self-stimulation (ICSS) |
| Key findings | Cannabinoid agonists did not lower intracranial self-stimulation thresholds, indicating they lack reinforcing properties in this paradigm; only the highest doses increased thresholds, suggesting an inhibitory, possibly anhedonic, effect on brain reward that appears mediated by CB1 receptors. |
Abstract
Addictive drugs have a number of commonalities in animal behavioral models. They lower intracranial self-stimulation (ICSS) thresholds, support self-administration, and produce conditioned place preference (CPP). However, cannabinoids appear atypical as drugs of abuse, since there are controversial data in the literature concerning their reinforcing properties. The aim of the present study was to examine the effects of cannabinoids on brain reward using the rate-frequency curve shift paradigm of ICSS. Male Sprague-Dawley rats were implanted with electrodes into the medial forebrain bundle (MFB). Rate-frequency functions were determined by logarithmically decreasing the number of cathodal pulses in a stimulation train from a value that sustained maximal responding to one that did not sustain responding. After brain stimulation reward thresholds stabilized rats received intraperitoneal (IP) injections of the potent CB1 receptor agonists WIN 55,212-2 (graded doses 0.1, 0.3, 1 and 3 mg/kg), CP 55,940 (graded doses 10, 30, 56 and 100 microg/kg), or HU-210 (graded doses 10, 30, 100 microg/kg). With the exception of the highest dose of all cannabinoid agonists tested, which significantly increased the threshold frequency required for MFB ICSS, all other doses of the tested drugs did not affect ICSS thresholds. The CB1 receptor antagonist SR141716A reversed the actions of WIN 55,212-2 and CP 55,940, but not HU-210. However, the selective CB1 cannabinoid receptor antagonist AM 251 counteracted the effect of HU-210. Both CB1 receptor antagonists, at the doses used in the present study, did not affect reward thresholds by themselves. The present results indicate that cannabinoid agonists do not exhibit reinforcing properties in the ICSS paradigm, but rather have an inhibitory influence on reward mechanisms. The results suggest that the anhedonic effects of cannabinoids are probably mediated by cannabinoid CB1 receptors.
Citations in the library
Cited by 8
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Optogenetic brain‐stimulation reward: A new procedure to re‐evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter‐Cre mice Addiction Biology February 3, 2021
- Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats. Neuropharmacology July 15, 2018
- Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference. Behavioural Brain Research July 15, 2014
- Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology August 2010
and 3 more in the library